Latest Industry Insights
How Can BioPlatforms Support the mRNA “Revolution”
The science and medicine worlds are experiencing a new revolution, and this time the protagonist is the mRNA molecule. In this article, we explore why bioplatforms support this revolution.
Automated Gas Chromatography Platform Aims To Simplify Lab Operations
PerkinElmer announced the launch of a new automated gas chromatography, the GC 2400 Platform. We spoke to Suneet Chadha to learn more about this latest introduction.
Extending the Reach of Psychedelic Therapy With Psychoplastogens
Delix Therapeutics is developing non-hallucinogenic psychedelics for use as at-home medications for mental health conditions. To find out more, we spoke to the CEO, Mark Rus.
A Platform That Could Help Identify and Target the “Undruggable”
We spoke to Neil Torbett, PhD, CEO of PhoreMost to learn more about “undruggable” targets and how the SITESEEKER® platform can identify these novel sites in the human proteome.
The Benefits of Automation for Antibody Discovery Workflows
At the recent Bio-IT World 2022 conference, Andrew LeBeau, associate vice president of product integrations at Dotmatics, gave a talk on the benefits that automation can bring to antibody discovery workflows. We spoke with LeBeau to find out more about these benefits and how Dotmatics’ approach meets one of the key themes of the conference, FAIR data principles.
How Researchers Are Bringing Sustainability to Scientific Discovery
Research is advancing exciting areas of science at an unprecedented pace, but the disposable materials, powered equipment and shipping associated with experiments, sample storage and transport of reagents contribute to high energy consumption and significant waste. How are researchers bringing sustainability to scientific discovery?
Cancer Research Horizons: Driving Innovation and Strengthening Academia–Industry Collaboration
In April 2022, Cancer Research UK unveiled Cancer Research Horizons, its new approach to driving innovation in the field. Technology Networks had the opportunity to speak with two members of Cancer Research Horizon’s executive leadership team to learn more about some of the cutting-edge experimental capabilities that will be used to interrogate cancer biology more thoroughly.
Molecular Spectroscopy Evolves To Meet Changing Pharma and Biopharma Needs
We spoke to Geoff Winkett and Michel van den Berge from Agilent, about the concerns they hear from their customers in the pharmaceutical and biopharmaceutical sector and how they are helping to address them.
Shielding Oncolytic Viruses From the Immune System To Improve Cancer Treatment
While oncolytic virus (OV) therapy has garnered increasing attention from the cancer research community, this therapeutic strategy doesn’t come without its challenges, as a patient’s immune system can sometimes mount a response to the OVs before they reach their intended target. To address this, Calidi Biotherapeutics has developed cell-based platforms to shield OVs from the immune system, so that they can effectively target and destroy the cancer cells.
Developing Therapeutics for Huntington’s Disease: Challenges, Opportunities and the Future
Dr. Christian Landles explains why it is so challenging to develop therapeutics for rare diseases such as HD, and discusses the potential of approaches that target mutant huntingtin protein to improve treatment options for HD patients.